SOR vs. HQL, PPT, MCI, TYG, KTF, MIY, MHN, PMO, HRZN, and RFI
Should you be buying Source Capital stock or one of its competitors? The main competitors of Source Capital include Abrdn Life Sciences Investors (HQL), Putnam Premier Income Trust (PPT), Barings Corporate Investors (MCI), Tortoise Energy Infrastructure (TYG), DWS Municipal Income Trust (KTF), BlackRock MuniYield Michigan Quality Fund (MIY), BlackRock MuniHoldings New York Quality Fund (MHN), Putnam Municipal Opportunities Trust (PMO), Horizon Technology Finance (HRZN), and Cohen & Steers Total Return Realty Fund (RFI). These companies are all part of the "investment offices, not elsewhere classified" industry.
Source Capital (NYSE:SOR) and Abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.
Source Capital received 20 more outperform votes than Abrdn Life Sciences Investors when rated by MarketBeat users. Likewise, 72.33% of users gave Source Capital an outperform vote while only 68.35% of users gave Abrdn Life Sciences Investors an outperform vote.
13.2% of Source Capital shares are held by institutional investors. Comparatively, 32.2% of Abrdn Life Sciences Investors shares are held by institutional investors. 77.0% of Source Capital shares are held by insiders. Comparatively, 10.1% of Abrdn Life Sciences Investors shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Source Capital has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Abrdn Life Sciences Investors has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.
In the previous week, Abrdn Life Sciences Investors had 14 more articles in the media than Source Capital. MarketBeat recorded 17 mentions for Abrdn Life Sciences Investors and 3 mentions for Source Capital. Abrdn Life Sciences Investors' average media sentiment score of 1.72 beat Source Capital's score of 0.00 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the news media.
Source Capital pays an annual dividend of $2.48 per share and has a dividend yield of 5.9%. Abrdn Life Sciences Investors pays an annual dividend of $1.33 per share and has a dividend yield of 9.7%.
Summary
Abrdn Life Sciences Investors beats Source Capital on 5 of the 8 factors compared between the two stocks.
Get Source Capital News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Source Capital Competitors List
Related Companies and Tools
